Xolair

Xolair (the trade name for Omalizumab), is a drug that has been approved to treat teenagers and adults with severe allergic asthma since its introduction in Australia in 2002. Approved by the U.S. Food and Drug Administration (FDA) in 2014, it has been held out as being particularly effective for people who cannot be treated with H1 antihistamines or do not benefit from high doses of corticosteroids. It has also been used to treat people who suffer chronically from hives.

A number of adverse side effects have been linked to the use of Xolair, including:

• Anaphylactic shock or anaphylaxis (a life-threatening allergic reaction)
• Increased risk of heart disease
• Increased risk of stroke
• Masking of warning signs of certain cancers

If you or someone you love has suffered injury after being prescribed Xolair, GetLegal has the tools and resources to help you find skilled legal representation to protect your rights. Visit our attorney directory, look for your geographic location and find the best lawyer for your situation.